A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two- Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults with Autism Spectrum Disorder (Peds)
Sponsor: Yamo Pharmaceuticals
Enrolling: Male and Female Patients
Clinic Visits: 10
IRB Number: 8301
Contact: Suvekcha Bhattachan: 914-997-5587 / suvekcha.bhattachan@nyspi.columbia.edu
Additional Study Information: This study will examine the possible benefits of an investigational drug called L1-79 in adolescents and young adults (12-21 years) diagnosed with autism spectrum disorder (ASD). Participation would involve ten visits to the Center for Autism and the Developing Brain in White Plains, NY over a period of 32 weeks. This will allow the study team to assess participants general health, perform developmental testing and study related medical care. You will not have to pay for any study-related treatments, lab tests or assessments. You will also receive $75 in reimbursements for in clinic study visits.
This study is closed
Jeremy Veenstra-VanderWeele, MD
Do You Qualify?
Is the participant between the ages of 12 and 21? Yes No
Has the participant been diagnosed with Autism Spectrum Disorder? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Suvekcha Bhattachan